- Home
- KPRX vs TCBIO Comparison
KPRX vs TCBIO Comparison
Compare KPRX & TCBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- TCBIO
- Stock Information
- Founded
- KPRX 1998
- TCBIO N/A
- Country
- KPRX United States
- TCBIO United States
- Employees
- KPRX N/A
- TCBIO 1818
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TCBIO Major Banks
- Sector
- KPRX Health Care
- TCBIO Finance
- Exchange
- KPRX Nasdaq
- TCBIO Nasdaq
- Market Cap
- KPRX 8.3M
- TCBIO N/A
- IPO Year
- KPRX N/A
- TCBIO N/A
- Fundamental
- Price
- KPRX $3.12
- TCBIO $19.91
- Analyst Decision
- KPRX Strong Buy
- TCBIO
- Analyst Count
- KPRX 1
- TCBIO 0
- Target Price
- KPRX $10.00
- TCBIO N/A
- AVG Volume (30 Days)
- KPRX 11.2K
- TCBIO N/A
- Earning Date
- KPRX 05-20-2025
- TCBIO N/A
- Dividend Yield
- KPRX N/A
- TCBIO N/A
- EPS Growth
- KPRX N/A
- TCBIO N/A
- EPS
- KPRX 0.87
- TCBIO N/A
- Revenue
- KPRX $16,020,000.00
- TCBIO N/A
- Revenue This Year
- KPRX N/A
- TCBIO N/A
- Revenue Next Year
- KPRX N/A
- TCBIO N/A
- P/E Ratio
- KPRX $3.68
- TCBIO N/A
- Revenue Growth
- KPRX N/A
- TCBIO N/A
- 52 Week Low
- KPRX $2.51
- TCBIO N/A
- 52 Week High
- KPRX $5.55
- TCBIO N/A
- Technical
- Relative Strength Index (RSI)
- KPRX 50.24
- TCBIO 55.30
- Support Level
- KPRX $3.18
- TCBIO $19.63
- Resistance Level
- KPRX $3.48
- TCBIO $20.10
- Average True Range (ATR)
- KPRX 0.19
- TCBIO 0.24
- MACD
- KPRX 0.02
- TCBIO 0.08
- Stochastic Oscillator
- KPRX 45.39
- TCBIO 78.95
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About TCBIO Texas Capital Bancshares Inc. Depositary Shares 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock Series B
Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers. It is a secured lender with the majority of the loans held for investment excluding mortgage finance loans and other national lines of business. The bank operates in Texas main metropolitan areas like Austin Dallas Fort Worth Houston and San Antonio.